Two cases of oligometastatic castration-resistant prostate cancer detected by diffusion-weighted whole-body imaging with background body signal suppression

IJU Case Rep. 2020 Feb 17;3(2):65-68. doi: 10.1002/iju5.12146. eCollection 2020 Mar.

Abstract

Introduction: Treatment for oligometastasis in prostate cancer has changed from systemic therapy to metastatic lesion-targeted therapy. Early detection of metastatic lesions and assessment of the treatment response have become very important. Therefore, we started to perfume assessments with whole-body magnetic resonance imaging, especially diffusion-weighted imaging with background body signal suppression, as a modality to detect metastasis in patients with prostate cancer.

Case presentation: We encountered two cases of castration-resistant prostate cancer in which oligometastasis was detected by diffusion-weighted imaging with background body signal suppression. Metastasis-directed therapy was initiated for to treat the lesions in each case. The treatment was effective for disease control and symptom relief. Diffusion-weighted imaging with background body signal suppression could detect new lesions at an early phase and delineate changes in lesions immediately after therapy.

Conclusion: Diffusion-weighted imaging with background body signal suppression enables early decision-making for metastasis-directed therapy compared with conventional imaging modalities. Further, metastasis-directed therapy targeting oligometastatic lesions detected by diffusion-weighted imaging with background body signal suppression may improve patients' overall survival and quality of life.

Keywords: CRPC; DWIBS; metastasis‐directed therapy; oligometastasis; prostate cancer.

Publication types

  • Case Reports